Devalla’s career reflects a commitment to using AI-enabled, cloud-based, and data-driven technologies to solve real-world ...

Unveiled at CES, the Awards Celebrate Visionaries Redefining the Automotive Industry Through SDV InnovationDownload Award ...

Executive promotion and trusted advisory leadership reinforce Supply Chain Now’s next chapter of growth serving 1M+ supply chain professionals. ATLANTA, GA, UNITED STATES, January 6, 2026 ...

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, ...

Ascidian Therapeutics and Forge Biologics have partnered to advance the development and manufacturing of ACDN-01.

The collaboration will support development of Ascidian's RNA exon editor therapy, ACDN-01, for treating the rare genetic eye disease.

Exchange Rate Volatility, Financial Fragility, Haiti, Remittances, Inflation, Monetary Policy, Structural Breaks, VECM Share ...

Guides who take tourists to enjoy the striking views of Sicily’s Mount Etna are up in arms over tougher restrictions imposed ...

Gene therapy ‘switch’ may offer non-addictive pain relief. New approach targets pain signals while leaving the rest of the brain untouched.

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as ...

Researchers achieve the first minimally invasive coronary artery bypass: Bethesda, Maryland Thursday, January 8, 2026, 11:00 Hrs [IST] In a world first, a team of researchers at t ...

Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...